{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:56:53Z","timestamp":1777604213679,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.clim.2014.09.012","type":"journal-article","created":{"date-parts":[[2014,9,28]],"date-time":"2014-09-28T15:46:25Z","timestamp":1411919185000},"page":"176-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Safety, efficacy, and pharmacokinetics\/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia\/lymphoma"],"prefix":"10.1016","volume":"155","author":[{"given":"Jonathan L.","family":"Berkowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Janik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donn M.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryalice","family":"Stetler-Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna H.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Fleisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole E.","family":"Urquhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilian H.","family":"Wharfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cody J.","family":"Peer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn K.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2014.09.012_bb0005","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"key":"10.1016\/j.clim.2014.09.012_bb0010","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1073\/pnas.79.18.5680","article-title":"Human T-cell leukemia\u2013lymphoma virus (HTLV) is in T but not B lymphocytes from a patient with cutaneous T-cell lymphoma","volume":"79","author":"Gallo","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2014.09.012_bb0015","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","article-title":"Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease","volume":"79","author":"Yoshida","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2014.09.012_bb0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.7326\/0003-4819-100-4-543","article-title":"T-cell lymphoproliferative syndrome associated with human T-Cell leukemia\/lymphoma virus","volume":"100","author":"Broder","year":"1984","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clim.2014.09.012_bb0025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","article-title":"Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia\u2013lymphoma: a proposal from an international consensus meeting","volume":"27","author":"Tsukasaki","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2014.09.012_bb0030","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia\u2013lymphoma. A report from the Lymphoma Study Group (1984\u201387)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2014.09.012_bb0035","series-title":"ASH Annual Meeting Abstracts","first-page":"3569","article-title":"A multicenter clinicopathologic experience of HTLV-1 ATLL: a retrospective 15 year review reveals little progress","volume":"110","author":"Phillips","year":"2007"},{"key":"10.1016\/j.clim.2014.09.012_bb0040","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1172\/JCI111379","volume":"73","author":"Waldmann","year":"1984","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2014.09.012_bb0045","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1182\/blood-2010-04-277418","article-title":"Autocrine\/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T cell leukemia","volume":"116","author":"Chen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clim.2014.09.012_bb0050","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V82.6.1701.1701","article-title":"The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia","volume":"82","author":"Waldmann","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clim.2014.09.012_bb0055","first-page":"6977","article-title":"IL-2R\u03b1-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2\/IL-2R\u03b1 interaction","volume":"60","author":"Phillips","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2014.09.012_bb0060","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1073\/pnas.86.24.10029","article-title":"A humanized antibody that binds to the interleukin 2 receptor","volume":"86","author":"Queen","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2014.09.012_bb0065","article-title":"Anti-Tac-H, a humanized antibody to the interleukin-2 receptor with new features for immunotherapy in malignant and immune disorders","volume":"50","author":"Junghans","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2014.09.012_bb0070","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199801153380304","article-title":"Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group","volume":"338","author":"Vincenti","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2014.09.012_bb0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00007890-199901150-00019","article-title":"Daclizumab double therapy study G. reduction of acute renal allograft rejection by daclizumab","volume":"67","author":"Nashan","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2014.09.012_bb0080","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","article-title":"Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I\/II clinical trial","volume":"96","author":"Nussenblatt","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2014.09.012_bb0085","doi-asserted-by":"crossref","first-page":"42.8","DOI":"10.1001\/archderm.138.1.42","article-title":"Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the Severity-Weighted Assessment Tool (SWAT)","volume":"138","author":"Stevens","year":"2002","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.clim.2014.09.012_bb0090","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1073\/pnas.95.4.1752","article-title":"Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies","volume":"95","author":"Junghans","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2014.09.012_bb0095","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.leukres.2005.06.007","article-title":"Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing","volume":"30","author":"Koon","year":"2006","journal-title":"Leuk. Res."},{"key":"10.1016\/j.clim.2014.09.012_bb0100","series-title":"WHO Handbook for Reporting Results of Cancer Treatment","year":"1979"},{"key":"10.1016\/j.clim.2014.09.012_bb0105","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.4049\/jimmunol.147.4.1352","article-title":"Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys","volume":"147","author":"Hakimi","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2014.09.012_bb0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/hyb.1985.4.91","article-title":"A monoclonal antibody 7G7\/B6 binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac","volume":"4","author":"Rubin","year":"1985","journal-title":"Hybridoma"},{"key":"10.1016\/j.clim.2014.09.012_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.clim.2014.09.012_bb0125","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia\u2013lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2014.09.012_bb0130","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2014.09.012_bb0135","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/TP.0b013e3181a23cb2","article-title":"The challenge of achieving target drug concentrations in clinical trials: experience from the symphony study","volume":"87","author":"Ekberg","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2014.09.012_bb0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cca.2010.08.013","article-title":"The Th17\/T reg imbalance exists in patients with heart failure with normal ejection fraction and heart failure with reduced ejection fraction","volume":"411","author":"Li","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.clim.2014.09.012_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003897.pub2","article-title":"Interleukin 2 receptor antagonists for kidney transplant recipients","volume":"1","author":"Webster","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.clim.2014.09.012_bb0150","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.transproceed.2010.05.083","article-title":"Anti-CD25 antibody (daclizumab) maintenance therapy in pancreas transplantation","volume":"42","author":"Kirchner","year":"2010","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.clim.2014.09.012_bb0155","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1399-3046.2008.01081.x","article-title":"Extended daclizumab monotherapy for rejection-free survival in non-adherent adolescent recipients of renal allografts","volume":"13","author":"Chaudhuri","year":"2009","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.clim.2014.09.012_bb0160","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1399-0012.2007.00757.x","article-title":"Use of low-dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient","volume":"22","author":"Kaplan","year":"2008","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.clim.2014.09.012_bb0165","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/01.TP.0000092950.54184.67","article-title":"Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation","volume":"76","author":"Sarwal","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2014.09.012_bb0170","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1046\/j.1365-2141.2002.03813.x","article-title":"Autocrine and\/or paracrine growth of adult T-cell leukaemia tumour cells by interleukin 15","volume":"119","author":"Kukita","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2014.09.012_bb0175","doi-asserted-by":"crossref","first-page":"14559","DOI":"10.1073\/pnas.251540598","article-title":"IL-15 plays a major role in the persistence of tax-specific CD8 cells in HAM\/TSP patients","volume":"98","author":"Azimi","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2014.09.012_bb0180","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1182\/blood-2007-09-113654","article-title":"Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clim.2014.09.012_bb0185","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1182\/blood-2010-09-305425","article-title":"CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM\/TSP","volume":"117","author":"Ju","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clim.2014.09.012_bb0190","first-page":"697","article-title":"Autocrine and\/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met","volume":"33","author":"Onimaru","year":"2008","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.clim.2014.09.012_bb0195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1474-4422(10)70033-8","article-title":"Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta","volume":"9","author":"Wynn","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clim.2014.09.012_bb0200","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1073\/pnas.0402653101","article-title":"Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta","volume":"101","author":"Bielekova","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2014.09.012_bb0205","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1073\/pnas.0601335103","article-title":"Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R\u03b1-targeted therapy (daclizumab) in multiple sclerosis","volume":"103","author":"Bielekova","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2014.09.012_bb0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13311-012-0147-4","article-title":"Daclizumab therapy for multiple sclerosis","volume":"10","author":"Bielekova","year":"2013","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clim.2014.09.012_bb0215","doi-asserted-by":"crossref","first-page":"U125","DOI":"10.1038\/nm.2365","article-title":"A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy","volume":"17","author":"Wuest","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2014.09.012_bb0220","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","article-title":"Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac","volume":"86","author":"Waldmann","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clim.2014.09.012_bb0225","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies","volume":"18","author":"Kreitman","year":"2000","journal-title":"J. Clin. Oncol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166161400223X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166161400223X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T21:29:32Z","timestamp":1689542972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152166161400223X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S152166161400223X"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2014.09.012","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, efficacy, and pharmacokinetics\/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia\/lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2014.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}